CORONA, Calif., June 3 Watson Pharmaceuticals,Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced todaythat it has received approval from the U.S. Food and Drug Administration("FDA") of its Abbreviated New Drug Application (ANDA) for Potassium-ChlorideExtended-Release Capsules USP in the 8mEq and 10mEq strengths.
Potassium-Chloride is the generic equivalent to KV Pharmaceutical'sMicro-K(R) Extencaps(R) USP and is indicated for the treatment of patientswith hypokalemia, with or without metabolic alkalosis, in digitalisintoxications, and in patients with hypokalemic familial periodic paralysis.For the 12-months ending March 2008, Micro-K(R) Extencaps(R) and its genericequivalents had total U.S. sales of approximately $80 million, according toIMS Health. Watson plans to launch its Potassium Chloride Extended-Releaseproduct during the third quarter of 2008. The specific launch date willdepend upon the timing of product validation activities and manufacturing oflaunch quantities.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leadingspecialty pharmaceutical company that develops, manufactures, markets, sellsand distributes brand and generic pharmaceutical products. Watson pursues agrowth strategy combining internal product development, strategic alliancesand collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit WatsonPharmaceuticals' Web site at http://www.watson.com.
Any statements contained in this press release that refer to future eventsor other non-historical facts are forward-looking statements that reflectWatson's current perspective of existing trends and information as of the dateof this release. Except as expressly required by law, Watson disclaims anyintent or obligation to update these forward-looking statements. Actualresults may differ materially from Watson's current expectations dependingupon a number of factors affecting Watson's business. These factors include,among others, difficulties or delays in manufacturing; the impact ofcompetitive products and pricing; market acceptance of and continued demandfor Watson's products; and other risks and uncertainties detailed in Watson'speriodic public filings with the Securities and Exchange Commission, includingbut not limited to Watson's Annual Report on Form 10-K for the year endedDecember 31, 2007.
SOURCE Watson Pharmaceuticals, Inc.